Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ACP3 | P15309 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GRM8 | O00222 | 4/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.37 |
| ▸ | GRM6 | O15303 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9190260 | 0.86 | TSHR (0.50) | CETPMEN1KMT2AHTTMAPT | |
| SCHEMBL12710497 | 0.81 | CETP (0.39) | CETPMAPT | |
| SCHEMBL5179155 | 0.77 | CETP (0.47) | CETPMEN1KMT2A | |
| SCHEMBL6137052 | 0.76 | CETP (0.48) | CETP | |
| SCHEMBL10684647 | 0.76 | PIM1 (0.41) | CETPLMNASMN1; SMN2 | |
| SCHEMBL28301358 | 0.74 | TSHR (0.57) | MEN1KMT2AHTTMAPTLMNA | |
| SCHEMBL7805557 | 0.74 | TSHR (0.48) | MEN1KMT2AMAPTLMNATSHR | |
| SCHEMBL4550413 | 0.73 | CETP (0.44) | CETPMAPTLMNASMN1; SMN2 | |
| SCHEMBL2437501 | 0.73 | TSHR (0.52) | MEN1KMT2AHTTMAPTLMNA | |
| SCHEMBL7801278 | 0.73 | NFE2L2 (0.55) | MEN1KMT2AHTTMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677382-B1 | HALOGENATED OXYAMINES, USED AS ENZYME INHIBITORS FOR PROPHYLAXIS OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISORDERS, AND AS ANTILIPEMIC AGENTS | PHARMACIA CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-6583183-B2 | N-phenyl-N-fused-benzyl aminoalcohol derivatives, useful for treating atherosclerosis and other coronary artery diseases | PHARMACIA CORPORATION | 2003-06-24 | — | — | US | disclosed |
| US-20020183397-A1 | Substituted n-phenyl-n-fused-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-12-05 | — | — | US | disclosed |
| US-6479552-B2 | TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | G.D. SEARLE & CO. | 2002-11-12 | — | — | US | disclosed |
| US-6458803-B1 | COMPOSITIONS AND METHODS FOR TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES. PREFERRED TERTIARY-HETEROALKYLAMINE COMPOUNDS ARE SUBSTITUTED N-PHENYL-N-HETEROARALKYL AMINOALCOHOLS. A PREFERRED SPECIFIC | G.D. SEARLE & CO. | 2002-10-01 | — | — | US | disclosed |
| US-6458849-B1 | METHOD OF TREATING OR PREVENTING A CEIP-MEDIATED DISORDER IN A SUBJECT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND FOR STROKES | G.D. SEARLE & CO. | 2002-10-01 | — | — | US | disclosed |
| US-6455519-B1 | TREATING ATHEROSCLEROSIS AND CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. | 2002-09-24 | — | — | US | disclosed |
| US-6451830-B1 | Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2002-09-17 | — | — | US | disclosed |
| US-6448295-B1 | TREATING CARDIOVASCULAR DISEASE; ATHEROSCLEROSIS, DYSLIPIDEMA HYPERCHOLESTEROLAEMIA; DECREASING CONCENTRATIONS OF LOW DENSITY LIPOPROTEIN AND RAISING LEVEL OF HIGH DENSITY LIPOPROTEIN | G.D. SEARLE & CO. | 2002-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183397-A1 | Substituted n-phenyl-n-fused-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | CETP 1/4885MEN1 4419/4885KMT2A 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.